BEAMSTART Logo

Hong Kong could be first to get Swiss start-up’s drug for diabetic eye disease

SCMP LogoSCMP9h ago

Hong Kong could be first to get Swiss start-up’s drug for diabetic eye disease - SCMP

Quick Summary:

Oculis’ OCS-01 eye drops, currently in phase 3 trials for diabetic macular edema, can be an alternative to injection, CEO says.

Only 60 per cent of DME patients saw improvements after receiving the injections, he added.

Hong Kong could be one of the first jurisdictions to use a novel treatment for diabetics suffering from a potentially blinding disease if a Swiss start-up’s drug is approved.

More Pictures

Hong Kong could be first to get Swiss start-up’s drug for diabetic eye disease - SCMP (Picture 1)

or

Article Details

Author / Journalist: Eric Ng

Category: Business

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-12-15 @ 11:30:11 (9 hours ago)

News Timezone: GMT +8:00

News Source URL: scmp.com

Language: English

Article Length: 156 words

Reading Time: 1 minutes read

Sentences: 4 lines

Sentence Length: 39 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © SCMP

News ID: 24410242

View Article Analysis

About SCMP

SCMP Logo

Main Topics: Business

Official Website: scmp.com

Update Frequency: 7 posts per day

Year Established: 1903

Headquarters: Hong Kong

News Last Updated: 4 hours ago

Coverage Areas: Hong Kong

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #42

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "Hong Kong could be first to get Swiss start-up’s drug for diabetic eye disease" has 156 words across 4 sentences, which will take approximately 1 - 2 minutes for the average person to read.

Which news outlet covered this story?

The story "Hong Kong could be first to get Swiss start-up’s drug for diabetic eye disease" was covered 9 hours ago by SCMP, a news publisher based in Hong Kong.

How trustworthy is 'SCMP' news outlet?

SCMP is a fully independent (privately-owned) news outlet established in 1903 that covers mostly business news.

The outlet is headquartered in Hong Kong and publishes an average of 7 news stories per day.

It's most recent story was published 4 hours ago.

What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #24410242
  • URL: https://beamstart.com/news/hong-kong-could-be-first-17342335222012

More News from SCMP

Latest Jobs

More Business News

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

Our Company

© Copyright 2024 BEAMSTART. All Rights Reserved.